MYOD1 as a prognostic indicator in rhabdomyosarcoma.
Atif A AhmedSultan HabeebuMidhat S FarooqiAlan S GamisElizabeth GonzalezTerrie FlattAshley ShermanLea F SurreyMichael A ArnoldMiriam ConcesSelene KooNikolina DioufaFrederic G BarrMaria G TsokosPublished in: Pediatric blood & cancer (2021)
These studies highlight the prognostic role of MYOD1 in non-ARMS. Lack of MYOD1 immunoreactivity is associated with poor prognosis in ERMS and SRMS. MYOD1 gene mutations are generally infrequent in pediatric RMS. Although mutations are predominant in SRMS, they may exceptionally occur in infantile ERMS.